These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33263865)

  • 1. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
    Lester J; Escriu C; Khan S; Hudson E; Mansy T; Conn A; Chan S; Powell C; Brock J; Conibear J; Nelless L; Nayar V; Zhuo X; Durand A; Amin A; Martin P; Zhang X; Pawar V
    BMC Cancer; 2021 May; 21(1):515. PubMed ID: 33962574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
    Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
    Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
    BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
    Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
    Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study.
    Li Y; Zhao J; Li R; Yao X; Dong X; Zhang R; Li Y
    Neoplasia; 2024 Nov; 57():101043. PubMed ID: 39226660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
    Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024; 20(22):1553-1563. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting.
    Simeone JC; Nordstrom BL; Patel K; Klein AB
    Future Oncol; 2019 Oct; 15(30):3491-3502. PubMed ID: 31497994
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting.
    Winfree KB; Torres AZ; Zhu YE; Muehlenbein C; Aggarwal H; Woods S; Abernethy A
    Curr Med Res Opin; 2019 May; 35(5):817-827. PubMed ID: 30421624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Piperdi B; Burke T
    Immunotherapy; 2019 Dec; 11(18):1541-1554. PubMed ID: 31774363
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
    Aguilar KM; Winfree KB; Muehlenbein CE; Zhu YE; Wilson T; Wetmore S; Nadler ES
    Adv Ther; 2018 Nov; 35(11):1905-1919. PubMed ID: 30341504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    Cowey CL; Scherrer E; Boyd M; Aguilar KM; Beeks A; Krepler C
    J Immunother; 2021 Jul-Aug 01; 44(6):224-233. PubMed ID: 33734142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Waliany S; Neal JW; Engel-Nitz N; Lam C; Lin F; Park L; Le L; Nagasaka M
    Clin Lung Cancer; 2024 Jun; 25(4):319-328.e1. PubMed ID: 38403548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.